Source: J Gastroenterol Hepatol | Posted 2 days ago
Long-term therapy for chronic hepatitis B: HBV DNA suppression leading to cirrhosis reversal;
Marcellin P, Asselah T; Journal of Gastroenterology and Hepatology (Apr 2013)
Since the licensing of the first treatment for chronic hepatitis B (CHB) in the nucleoside/tide analogue (NA) class almost 15 years ago, considerable progress has been made in improving drug efficacy and safety with highly potent NAs exhibiting a high barrier to resistance. Physicians are now able to treat patients safely for many years and to be able to see convincing improvements in histology, including regression of fibrosis and even reversal of cirrhosis. The robust data that have been generated help us build confidence that we can now offer patients with CHB long-term, disease-modifying therapy that can alter the natural course of disease and help prevent the morbidity and mortality associated with it. 作者: StephenW 时间: 2013-4-17 20:11